News

Connell’s appointment was effective immediately after the Annual General Meeting of the Company on November 15, 2024.

At the ESCRS meeting, Sir Harold Ridley’s legacy was put on display in a pop-up museum installation

Dosing in the first phase of the phase 1/2 OCU410ST GARDian trial for Stargardt disease is complete.

Special circumstances must be considered for plateau dwellers, such as Tibetans, mountaineers, and garrison officers, who are exposed to low humidity, strong ultraviolet rays, cold and dry weather, and low pressure and hypoxia

The NHS is expanding the use of optical coherence tomography to enhance diabetic eye care, aiming to improve early detection of diabetic retinopathy and reduce the backlog of hospital appointments.

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research.

The program aims to expand access and affordability for Harrow's ophthalmic pharmaceutical products through targeted price reductions and a strategic partnership with GoodRx.

Research is needed to establish the best diagnostic and management strategies for increasingly common condition

The CHMP has recommended FYB203 for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.

Gupta is a nationally recognized retinal surgeon and an entrepreneur whose knowledge and experience on the phases of drug development and medical devices.

Cerebral/cortical visual impairment (CVI) is a leading cause of childhood blindness, caused by brain damage to visual pathways. Researchers are refining its definition and diagnostic methods to improve early detection and treatment, enhancing outcomes for affected children.

Research needed to establish best diagnostic and management strategies for increasingly common condition.

The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025.

Avant Technologies and Ainnova Tech have partnered to develop a low-cost retinal camera integrated with Ainnova’s Vision AI platform for early detection of ocular and systemic diseases. The technology will be marketed as a SaaS platform for primary care settings.

After closing, the combined company is expected to operate under the name Kalaris Therapeutics, Inc.

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.

ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease who required frequent anti-VEGF injections before enrolling in the trial.

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human trial.

The incidence was comparable to that of daily wear soft contact lenses

Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks.

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing a therapy for dry age-related macular degeneration, one of the leading causes of blindness in older adults.

A Q&A with PPP Committee Cornea/External Disease Panel member Daniel S. Choi, MD.

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development.

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.